For research use only. Not for therapeutic Use.
Coblopasvir dihydrochloride（Cat No.:I044121）is a potent NS5A inhibitor developed for the treatment of hepatitis C virus (HCV) infection. It targets the NS5A protein, which plays a crucial role in viral RNA replication and assembly, thereby inhibiting HCV replication across multiple genotypes. Coblopasvir is often studied in combination with other direct-acting antivirals (DAAs) to enhance antiviral efficacy and reduce resistance. With favorable pharmacokinetic properties and broad-spectrum antiviral activity, Coblopasvir dihydrochloride is a valuable candidate in antiviral research, particularly in the development of interferon-free HCV therapeutic regimens.
| CAS Number | 1966138-53-3 |
| Synonyms | methyl N-[(2S)-1-[(2S)-2-[5-[4-[7-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]-1,3-benzodioxol-4-yl]phenyl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate;dihydrochloride |
| Molecular Formula | C41H52Cl2N8O8 |
| Purity | ≥95% |
| IUPAC Name | methyl N-[(2S)-1-[(2S)-2-[5-[4-[7-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]-1,3-benzodioxol-4-yl]phenyl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate;dihydrochloride |
| InChI | InChI=1S/C41H50N8O8.2ClH/c1-22(2)32(46-40(52)54-5)38(50)48-17-7-9-30(48)36-42-19-28(44-36)25-13-11-24(12-14-25)26-15-16-27(35-34(26)56-21-57-35)29-20-43-37(45-29)31-10-8-18-49(31)39(51)33(23(3)4)47-41(53)55-6;;/h11-16,19-20,22-23,30-33H,7-10,17-18,21H2,1-6H3,(H,42,44)(H,43,45)(H,46,52)(H,47,53);2*1H/t30-,31-,32-,33-;;/m0../s1 |
| InChIKey | NQXPKJCTLPFQIS-KJIUXTSNSA-N |
| SMILES | CC(C)[C@@H](C(=O)N1CCC[C@H]1C2=NC=C(N2)C3=CC=C(C=C3)C4=C5C(=C(C=C4)C6=CN=C(N6)[C@@H]7CCCN7C(=O)[C@H](C(C)C)NC(=O)OC)OCO5)NC(=O)OC.Cl.Cl |
| Chemistry Calculators | Dilution Calculator In vivo Formulation Calculator Molarity Calculator Molecular Weight Calculator Reconstitution Calculator |
